Chinese Name: TAK788
English Name: TAK-788
Purity: 99.0%
Product Category: Intermediate

Background Information:
On January 15, 2020, the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) announced that TAK-788, developed by Takeda, has received implicit clinical trial approval in China.
TAK-788 is a next-generation, potent, and selective small molecule tyrosine kinase inhibitor (TKI), specifically developed to treat non-small cell lung cancer (NSCLC) patients with EGFR exon 20 insertion mutations.

Keywords:
TAK788; TAK-788; AP 32788